Входя на эту страницу, Вы подтверждаете, что являетесь  медицинским работником.

Status message

Not the entire site translated, but only to "Magazine"

Concept, Classification and Clinical Differentiation of Negative Symptoms in Schizophrenia

S.N. Mosolov, P.A. Yaltonskaya

Moscow Research Institute of Psychiatry – a branch of the FSBI “National Medical Research Center for Psychiatry and Addiction named after V.P. Serbian” Ministry of Health of Russian Federation, Moscow, Russia

Abstract: The negative symptoms of schizophrenia include volitional (motivational) (avolution, anhedonia and social isolation) and emotional (alogia and blunted affect) disorders. Negative symptoms worsen patient quality of life and functioning. From a diagnostic point of view, it is important to distinguish between primary as an integral part of schizophrenia and secondary negative symptoms as a result of positive symptoms, comorbid depression, side effects of antipsychotics, substance abuse or social isolation. The different trajectories of primary and secondary negative symptoms during the course of schizophrenia are proposed as an important discriminating factor.  Clinical aspects of negative symptoms in schizophrenia, their definition, phenomenology, factor structure and classification are discussed. The historical and modern concepts of the paradigm of positive and negative disorders in schizophrenia and the likely pathophysiological mechanisms of negative symptoms are presented. In a comparative aspect, registration tools and psychometric assessment of negative symptoms are described in detail.

Contact: profmosolov@mail.ru

Citation: Mosolov S.N., Yaltonskaya  P.A. Concept, classification and clinical differentiation of negative symptoms in schizophrenia // Sovrem. ter. psih. rasstrojstv. – 2020. – Vol. 1. – P. 2-14. – DOI: 10.21265/PSYPH.2020.15.30.001

References:

1.    Bobes J., Arango C., Garcia-Garcia M. et al. Prevalence of Negative Symptoms in Outpatients With Schizophrenia Spectrum Disorders Treated With Antipsychotics in Routine Clinical Practice: Findings From the CLAMORS Study // J Clin Psychiatry. – 2009. – Vol. 71, No. 3. – P. 280–286.
2.    Galderisi S., Mucci A., Bitter I. et al. Persistent negative symptoms in first episode patients with schizophrenia: Results from the European First Episode Schizophrenia Trial // Eur Neuropsychopharmacol. – 2013. – Vol. 23, No. 3. – P. 196–204.
3.    Patel R., Jayatilleke N., Broadbent M., et al. Negative symptoms in schizophrenia: a study in a large clinical sample of patients using a novel automated method // BMJ Open. – 2015. – Vol. 5, No. 9. – P. e007619. 
4.    Möller H.J., Jager M., Riedel M. et al. The Munich 15-year follow-up study (MUFSSAD) on first-hospitalized patients with schizophrenic or affective disorders: Assessing courses, types and time stability of diagnostic classification // Eur Psychiatry. – 2010. – Vol. 26. – P. 231–243.
5.    Strauss G.P., Horan W.P., Kirkpatrick B. et al. Deconstructing negative symptoms of schizophrenia: Avolition–apathy and diminished expression clusters predict clinical presentation and functional outcome // J Psychiatr Res. – 2013. – Vol. 47. – P. 783–790.
6.    Neznanov N.G., Shmukler A.B., Kostyuk G.P. i soavt. Pervy`j psixoticheskij e`pizod: e`pidemiologicheskie aspekty` organizacii pomoshhi // Social`naya i klinicheskaya psixiatriya. – 2018. – T. 28, № 3. – S. 5–11.
7.    Psixiatriya. Nacional`noe rukovodstvo. Kratkoe izdanie / pod red. T.B. Dmitrievoj, V.N. Krasnova, N.G. Neznanova, V.Ya. Semke, A.S. Tiganova. – M.: GE`OTAR-Media, 2012. – 624 s. – S. 290–308.
8.    Dzhons P.B., Bakli P.F. Shizofreniya. Klinicheskoe rukovodstvo / per. s angl. pod obshh. red. S. N. Mosolova. M.: MEDpress-inform, 2008. – 192 s.
9.    Mosolov S.N. Nekotory`e aktual`ny`e teoreticheskie problemy` diagnostiki, klassifikacii, nejrobiologii i terapii shizofrenii: sravnenie zarubezhnogo i otechestvennogo podxodov // Zhurnal nevrologii i psixiatrii imeni C.C. Korsakova. – 2010. – T. 110, № 6. – S. 4–11.
10.    Galderisi S., Bucci P., Mucci A. et al. Categorical and dimensional approaches to negative symptoms of schizophrenia: focus on long-term stability and functional outcome // Schizophr Res. – 2013. – Vol. 147, No. 1. – P. 157–162.
11.    Kirkpatrick B. Developing Concepts in Negative Symptoms: Primary vs Secondary and Apathy vs Expression // J Clin Psychiatry. – 2014. – Vol. 75. – P. 3–7.
12.    Austin S.F., Mors O., Budtz-Jørgensen E. et al. Long-term trajectories of positive and negative symptoms in first episode psychosis: A 10 year follow-up study in the OPUS cohort // Schizophr Res. – 2015. – Vol. 168. – P. 84–91.
13.    Mosolov S.N., Czukarzi E`.E`. Psixofarmakoterapiya shizofrenii // Psixiatriya: nacional`noe rukovodstvo / pod red. N.G. Neznanova, Yu.A. Aleksandrovskogo. – M.: GE`OTAR-Media, 2018. – 624 s. – S. 299–328.
14.    Haslam J. Observations on madness and melancholy. – London: J. Callow, 1809. – 345 p.
15.    Pearce J.M. Positive and negative cerebral symptoms: the roles of Russell Reynolds and Hughlings Jackson // J Neurol Neurosurg Psychiatry. – 2004. – Vol. 75, No. 8. – P. 1148.
16.    Jackson J.H. On temporary mental disorders after epileptic paroxysms // West Riding Lunatic Asylum Med Rep. – 1885 – Vol. 5. – P. 105–129.
17.    Kraepelin E. Die Erscheinungsformen des Irreseins // Für Gesamte Neurol Psychiatr. – 1920. – Vol. 62. – P. 1–29.
18.    Bleuler E. Dementia praecox oder Gruppe der Schizophrenien. – Leipzig: Deuticke, 1911.
19.    Strauss J.S., Carpenter W.T. Jr., Bartko J.J. The diagnosis and understanding of schizophrenia. Part III. Speculations on the processes that underlie schizophrenic symptoms and signs // Schizophr Bull. – 1974. – Vol. 11. – P. 61–69.
20.    Huber G. Reine Defektsyndrome und Basisstadien endogener Psychosen // Fortschr Neurol Psychiat. – 1966. – Vol. 34. – P. 409–415.
21.    Ebel H., Gross G., Klosterkötter J. et al. Basic symptoms in schizophrenic and affective psychoses // Psychopathology. – 1989. – Vol. 22, No. 4. – P. 224–232.
22.    Janzarik W. Schizophrene Verlaufe. Eine strukturdynamische Interpretation. – Berlin: Springer, 1968.
23.    Huber G. Das Konzept substratnaher Basissymptome und seine Bedeutung fuer Theorie und Therapie schizophrener Erkrankungen // Nervenarzt. – 1983. – Vol.  54. – P. 23–32. 
24.    Shizofreniya (mul`tidisciplinarnoe issledovanie).– M.: Medicina, 1972. – S. 5–15. 
25.    Crow T.J. Molecular pathology of schizophrenia: More than one dimension of pathology? // British Medical Journal. – 1980. – Vol. 280. – P. 66–68.
26.    Andreasen N.C. Thought, language, and communication disorders I. Clinical assessment, definition of terms, and evaluation of their reliability // Arch Gen Psychiatry. – 1979. – Vol. 36, No. 12. – P. 1315–1321.
27.    Klein D. Endogenomorphic depression // Arch Gen Psychiatry. – 1974. – Vol. 31, No. 4. – P. 447–454.
28.    Andreasen N.C. Negative symptoms in schizophrenia. Definition and reliability // Arch Gen Psychiatry. – 1982. – Vol. 39, No. 7. – P. 784–788.
29.    Peralta V., Cuesta M.J. Dimensional structure of psychotic symptoms: an item-level analysis of SAPS and SANS symptoms in psychotic disorders // Schizophr Res. – 1999. – Vol. 38, No. 1. – P. 13–26.
30.    Selten J.P., Wiersma D., van den Bosch R.J. Discrepancy between subjective and objective ratings for negative symptoms // J Psychiatr Res. – 2000. – Vol. 34, No. 1. – P. 11–13.
31.    Lyne J.P., Turner N., Clarke M. Treat negative symptoms of schizophrenia early on // BMJ. – 2012. – Vol. 27. – P. 344.
32.    Kirkpatrick B., Fenton W.S., Carpenter W.T. Jr. et al. The NIMH‐MATRICS consensus statement on negative symptoms // Schizophr Bull. – 2006. – Vol. 32, No. 2. – P. 214–219.
33.    Pizzagalli D.A. The “anhedonia paradox” in schizophrenia: insights from auffective neuroscience // Biol Psychiatry. – 2010. – Vol. 67, No. 10. – P. 899–901.
34.    Blanchard J.J., Cohen A.S. The structure of negative symptoms within schizophrenia: implications for assessment // Schizophr Bull. – 2006. – Vol. 32. – P. 238–245.
35.    Horan W.P., Kring A.M., Gur R.E. et al. Development and psychometric validation of the Clinical Assessment Interview for Negative Symptoms (CAINS) // Schizophr Res. – 2011. – Vol. 132. – P. 140–145.
36.    Galderisi S., Mucci A., Buchanan R.W. et al.  Negative symptoms of schizophrenia: new developments and unanswered research questions // Lancet Psychiatry. – 2018. – Vol. 5, No. 8. – P. 664–677.
37.    Mucci A., Vignapiano A., Bitter I., et al. A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale // Eur Neuropsychopharmacol. – 2019. – Vol. 29, No. 8. – P. 947–959.
38.    Strauss G.P., Esfahlani F.Z., Galderisi S. et al. Network analysis reveals the latent structure of negative symptoms in schizophrenia // Schizophr Bull. 2018. – Vol. 29. – P. 133.
39.    Carpenter W.T. Jr., Heinrichs D.W., Wagman A.M. Deficit and nondeficit forms of schizophrenia: the concept // Am J Psychiatry. – 1988. – Vol. 145, No. 5. – P. 578–583. 
40.    Kirkpatrick B., Buchanan R.W., McKenney P.D. et al. The Schedule for the Deficit syndrome: an instrument for research in schizophrenia // J Psychiatry Res. – 1989. – Vol. 30, No. 2. – P. 119–123.
41.    Kirkpatrick B., Buchanan R.W., Ross D.E. et al. WTA separate disease within the syndrome of schizophrenia // Jr Arch Gen Psychiatry. – 2001. – Vol. 58, No. 2. – P. 165–171.
42.    Amador X.F., Flaum M., Andreasen N.C. et al. Awareness of illness in schizophrenia and schizoaffective and mood disorders // Jr Arch Gen Psychiatry. – 1994. – Vol. 51. – P. 826–836.
43.    Marder S., Galderisi S. The current conceptualization of negative symptoms in schizophrenia // World Psychiatry. – 2017. – Vol. 16. – P. 14–24. 
44.    Kirkpatrick B., Strauss G.P., Nguyen L. et al. The brief negative symptom scale: psychometric properties // Schizophr Bull. – 2011. – Vol. 37, No. 2. – P. 300–305. 
45.    Krause M., Zhu Y., Huhn M. et al. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis // Eur Arch Psychiatry Clin Neurosci. – 2018. – Vol. 268, No. 7. – P. 625–639. 
46.    Millan M.J., Andrieux A., Bartzokis G. et al. Altering the course of schizophrenia: progress and perspectives // Nat Rev Drug Discov. – 2016. – Vol. 15. – P. 485–515.
47.    Mosolov S.N. Shkaly` psixometricheskoj ocenki simptomatiki shizofrenii i koncepciya pozitivny`x i negativny`x rasstrojstv. – M.: Novy`j czvet, 2001. – 238 s.
48.    Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia // Schizophr Bull. – 1987. – Vol. 13, No. 2. – P. 261–276.
49.    Buchanan R.W., Panagides J., Zhao J., et al. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia // J Clin Psychopharmacol. – 2012. – Vol. 32, No. 1. – P. 36–45.
50.    Mayerhoff A.D., Loebel A.D., Alvir J.M.J. et al (1994): The deficit state in first-episode schizophrenia. //Am J Psychiatry. – 1994. – Vol. 151. – P. 1417–1429.
51.    Edwards S.J., Braunholtz D.A., Lilford R.J., et al. Ethical issues in the design and conduct of cluster randomised controlled trials // BMJ. – 1999. – Vol. 318, No. 7195. – P. 1407–1409. 
52.    Malla A., Norman R., McLean T. et al. A Canadian programme for early intervention in non-Canadian programme for early intervention in nonaffective psychotic disorders // Australian and New Australian and New Zealand Journal of Psychiatry. – 2003. – Vol. 37. – P. 407–413.
53.    Buchanan R.W. Persistent negative symptoms in schizophrenia: an overview // Schizophr Bull. – 2007. – Vol. 33. – P. 1013–1022.
54.    Stauffer V.L., Song G., Kinon B.J., et al. Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms // Schizophr Res. – 2012. – Vol. 134. – P. 195–201.
55.    Alphs L., Panagides J., Lancaster S. Asenapine in the treatment of negative symptoms of schizophrenia: clinical trial design and rationale // Psychopharmacol Bull. – 2007. – Vol. 40. – P. 41–53.
56.    Riedel M., Muller N., Strassnig M. et al. Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms // Eur Arch Psychiatry Clin Neurosci. – Vol. 255, No. 6. – P. 432–437.
57.    Mucci A., Merlotti E., Üçok A. et al. Primary and persistent negative symptoms: Concepts, assessments and neurobiological bases // Schizophr Res. – 2017. – Vol. 186. – P. 19–28.
58.    Marder S.R., Alphs L., Anghelescu I-G. et al. Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia // Schizophr Res. – 2013. – Vol. 150, No. 2–3. – P. 328–333.
59.    Rabinowitz J., Berardo C.G., Bugarski-Kirola D. et al. Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: a CATIE analysis // Schizophr Res. – 2013. – Vol. 150. – P. 339–342.
60.    Marder S.R., Davis J.M., Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials // J Clin Psychiatry. – 1997. – Vol. 58, No. 12. – P. 538–546.
61.    Axelrod B.N., Goldman R.S., Alphs L.D., Validation of the 16-item Negative Symptom Assessment // J Psychiatr Res. – 1993. – Vol. 27, No. 3. – P. 253–258.
62.    Alphs L., Morlock R., Coon C. et al. The 4-Item Negative Symptom Assessment (NSA-4) Instrument: A Simple Tool for Evaluating Negative Symptoms in Schizophrenia Following Brief Training // Psychiatry (Edgmont). – 2010. – Vol. 7, No. 7. – P. 26–32.
63.    Mucci A., Galderisi S., Merlotti E. et al. The Brief Negative Symptom Scale (BNSS): Independent validation in a large sample of Italian patients with schizophrenia // Eur Psychiatry. – 2015. – Vol. 30. – P. 641–647.
64.    Dollfus S., Mach C., Morello R. Self-Evaluation of Negative Symptoms: A Novel Tool to Assess Negative Symptoms // Schizophr Bull. – 2016. – Vol. 42. – P. 571–578. 
65.    Llerena K., Park S.G., McCarthy J.M. et al. The Motivation and Pleasure Scale-Self-Report (MAP-SR): reliability and validity of a self-report measure of negative symptoms // Compr Psychiatry. – 2013. – Vol. 54, No. 5. – P. 568–574.
66.    Addington D., Addington J., Schissel B. A depression rating scale for schizophrenics // Schizophr Res. – 1990. – Vol. 3, No. 4. – P. 247–251.
67.    Chiappelli J., Nugent K.L., Thangavelu K. et al. Assessment of trait and state aspects of depression in schizophrenia // Schizophr Bull. – 2014. – Vol. 40, No. 1. – P. 132–142.
68.    Lincoln T.M., Dollfus S., Lyne J. Current developments and challenges in the assessment of negative symptoms // Schizophr Res. – 2017. – Vol. 186. – P. 8–18.
69.    Barch D.M., Gold J.M., Kring A.M. Paradigms for Assessing Hedonic Processing and Motivation in Humans: Relevance to Understanding Negative Symptoms in Psychopathology // Schizophr Bull. – 2017. – Vol. 43. – P. 701–705.
70.    Barnes T.R.E. Antipsychotic Drugs and Their Side-Effects. Academic Press. – 2013. – P. 89–101.
71.    Zhislin S.G. Ocherki klinicheskoj psixiatrii. – M.: Medicina, 1965. – 320 c.
72.    Niss A.I. O nekotory`x klinicheskix osobennostyax i social`nom statuse bol`ny`x vyalotekushhej shizofreniej, sostoyashhix na dispansernom uchete // Novy`e metody` terapii i reabilitacii psixicheski bol`ny`x vo vnebol`nichny`x usloviyax. – M., 1979. – S. 123–125.
73.    Bischof M., Kaiser S. Negativsymptome – Diagnostik und Therapie // InFo Neurol Psychiatr. – 2016. – Vol. 14.
74.    Krynicki C.R., Upthegrove R., Deakin J.F.W. et al. The relationship between negative symptoms and depression in schizophrenia: a systematic review // Acta Psychiatr Scand. – 2018. – Vol. 137, No. 5. – P. 380–390.
75.    Chen L., Johnston J.A., Kinon B.J. et al. The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial // BMC Psychiatry. – 2013. – Vol. 13. – P. 320.
76.    Oshima I., Mino Y., Inomata Y. Effects of environmental deprivation on negative symptoms of schizophrenia: A nationwide survey in Japan's psychiatric hospitals // Psychiatry Res. – 2005. – Vol. 136. – P. 163–171.
77.    Schmits E., Quertemont E. So called “soft” drugs: Cannabis and the amotivational syndrome // Rev Médicale Liège. – 2013. – Vol. 68. – P. 281–286.
78.    Neznanov N.G., Marty`nixin N.G., Mosolov S.N. Diagnostika shizofrenii v Rossii: rezul`taty` onlajn-oprosa vrachej-psixiatrov Chast` 1. Ispol`zovanie MKB-10 // Sovremennaya terapiya psixicheskix rasstrojstv. – 2019. – № 1. – S. 2–19.
79.    Kirschner M., Hager O.M., Bischof M. et al. Ventral striatal hypoactivation is associated with apathy but not diminished expression in patients with schizophrenia // J Psychiatry Neurosci JPN. – 2016. – Vol. 41. – P. 152–161.
80.    Galderisi S., Merlotti E., Mucci A. Neurobiological background of negative symptoms // Eur Arch Psychiatry Clin Neurosci. – 2015. – Vol. 265. – P. 543–558.
81.    Crow T.J. The two-syndrome concept: origins and current status // Schizophr Bull. – 1985. – Vol. 11, No. 3. – P. 471–486.
82.    Hovington C.L., Lepage M. Neurocognition and neuroimaging of persistent negative symptoms of schizophrenia // Expert Rev Neurother. – 2012. – Vol. 12, No.1. – P. 53–69.
83.    International Review of Neurobiology. – 2019. – Vol. 144. – P. 95–141.
84.    Caravaggio F., Fervaha G., Menon M. et al. The neural correlates of apathy in schizophrenia: An exploratory investigation // Neuropsychologia. – 2018. – Vol. 118, No. Pt B. – P. 34–39. 
85.    John J.P., Rangaswamy M., Thennarasu K. et al. EEG power spectra differentiate positive and negative subgroups in neuroleptic-naive schizophrenia patients // J Neuropsychiatry Clin Neurosci. – 2009. – Spring. – Vol. 21, No. 2. – P. 160–172.
86.    Itoh T., Sumiyoshi T., Higuchi Y. et al. LORETA analysis of three-dimensional distribution of δ band activity in schizophrenia: relation to negative symptoms // Neurosci Res. – 2011. – Vol. 70, No. 4. – P. 442–448.
87.    Ribeyre J.M., Lesieur P., Varoquaux O. et al. A comparison of plasma homovanillic acid in the deficit and nondeficit subtypes of schizophrenia // Biol Psychiatry. – 1994. – Vol. 36, No. 4. – P. 230–236.
88.    Toda M., Abi-Dargham A. Dopamine hypothesis of schizophrenia: making sense of it all // Curr Psychiatry Rep. – 2007. – Vol. 9, No. 4. – P. 329–336.
89.    Karlson A., Lekrub`e I. Dofaminovaya teoriya patogeneza shizofrenii. Rukovodstvo dlya vrachej / pod red. Mosolova S.N. – London, 2004. – 167 s.
90.    Siris S.G., Bermanzohn P.C., Gonzalez A. et al. The use of antidepressants for negative symptoms in a subset of schizophrenic patients // Psychopharmacol Bull. – 1991. – Vol. 27, No. 3. – P. 331–335.
91.    Yoshimura R., Hori H., Katsuki A. et al. Serum levels of brain-derived neurotrophic factor (BDNF), proBDNF and plasma 3-methoxy-4-hydroxyphenylglycol levels in chronic schizophrenia // Ann Gen Psychiatry. – 2016. – Vol. 15. – P. 1.
92.    Winograd-Gurvich C., Fitzgerald P.B., Georgiou-Karistianis N. et al. Negative symptoms: A review of schizophrenia, melancholic depression and Parkinson’s disease // Brain Res Bull. – 2006. – Vol. 70, No. 4–6. – P. 312–321.
93.    Möller H.J. Management of the negative symptoms of schizophrenia: new treatment options // CNS Drugs. – 2003. – Vol. 17, No. 11. – P. 793–823.
94.    Goff D.C., Evins A.E. Negative symptoms in schizophrenia: neurobiological models and treatment response // Harv Rev Psychiatry. – 1998. – Vol. 6, No. 2. – P. 59–77.
95.    Fawzi M.H., Fawzi M.M., Said N.S. C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia // Psychiatry Res. – 2011. – Vol. 190, No. 1. – P. 91–97.
96.    Prasad K.M., Eack S.M., Goradia D. et al. Progressive gray matter loss and changes in cognitive functioning associated with exposure to herpes simplex virus 1 in schizophrenia: a longitudinal study // Am J Psychiatry. – 2011. – Vol. 168, No. 8. – P. 822–830.
97.    Mosolov S.N. Dostizheniya, problemy` i perspektivy` farmakoterapii psixicheskix rasstrojstv. // Mezhdisciplinarny`e podxody` k izucheniyu psixicheskogo zdorov`ya cheloveka i obshhestva. T. 1. – M.: KDU, 2019. – 484 s. – C. 21–32. 
98.    Goff D.C. D-cycloserine in Schizophrenia: New Strategies for Improving Clinical Outcomes by Enhancing Plasticity // Curr Neuropharmacol. – 2017. – Vol. 15, No. 1. – P. 21–34.
99.    Van Os J., Rutten B.P., Poulton R. Gene-Environment Interactions in Schizophrenia: Review of Epidemiological Findings and Future Directions // Schizophr Bull. – 2008. – Vol. 34. – P. 1066–1082.
100.    Esterberg M.L., Trotman H.D., Holtzman C. et al. The impact of a family history of psychosis on age-at-onset and positive and negative symptoms of schizophrenia: a meta-analysis // Schizophr Res. – 2010. – Vol. 120, No. 1–3. – P. 121–130.
101.    Potkin S.G., Macciardi F., Guffanti G. et al. Identifying gene regulatory networks in schizophrenia // Neuroimage. – 2010. – Vol. 53, No. 3. – P. 839–847.
102.    Zai G., Robbins T.W., Sahakian B.J. et al. A review of molecular genetic studies of neurocognitive deficits in schizophrenia // Neurosci Biobehav Rev. – 2017. – Vol. 72. – P. 50–67.
103.    Green M.J., Cairns M.J., Wu J. et al. Australian Schizophrenia Research Bank. Genome-wide supported variant MIR137 and severe negative symptoms predict membership of an impaired cognitive subtype of schizophrenia // Mol Psychiatry. – 2013. – Vol. 18, No. 7. – P. 774–780.